NCT03122223: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03122223 |
|---|---|
| Title | A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 16, 2018 |
| Completion date | July 30, 2020 |
| Required reporting date | July 30, 2021, midnight |
| Actual reporting date | Oct. 15, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |